How to Get Cost-Effectiveness Analysis Right? The Case of Vaccine Economics in Latin America.

ABSTRACT:

Background

In middle-income countries, vaccines against pneumococcal disease, rotavirus, and human papilloma virus are in general more costly, not necessarily cost saving, and less consistently cost-effective than earlier generation vaccines against measles, diphtheria, tetanus, and pertussis. Budget impact is also substantial; public spending on vaccines in countries adopting new vaccines is, on average, double the amount of countries that have not adopted. Policymakers must weigh the costs and benefits of the adoption decision carefully, given the low coverage of other kinds of cost-effective health and nonhealth interventions in these same settings and relatively flat overall public spending on health as a share of gross domestic product (GDP) over time.

Objective

This pa

SUBMITTER: Glassman A 

PROVIDER: S-EPMC5193155 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature